JP2017526700A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526700A5 JP2017526700A5 JP2017513044A JP2017513044A JP2017526700A5 JP 2017526700 A5 JP2017526700 A5 JP 2017526700A5 JP 2017513044 A JP2017513044 A JP 2017513044A JP 2017513044 A JP2017513044 A JP 2017513044A JP 2017526700 A5 JP2017526700 A5 JP 2017526700A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- monoclonal antibody
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 13
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 13
- 229960002756 azacitidine Drugs 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 10
- 229950009791 durvalumab Drugs 0.000 claims description 7
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 9
- 206010033128 Ovarian cancer Diseases 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 229950010773 pidilizumab Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 231100000402 unacceptable toxicity Toxicity 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000006842 hematologic response Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047463P | 2014-09-08 | 2014-09-08 | |
| US62/047,463 | 2014-09-08 | ||
| PCT/US2015/048812 WO2016040238A1 (en) | 2014-09-08 | 2015-09-08 | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017526700A JP2017526700A (ja) | 2017-09-14 |
| JP2017526700A5 true JP2017526700A5 (enExample) | 2018-03-08 |
Family
ID=54150681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513044A Pending JP2017526700A (ja) | 2014-09-08 | 2015-09-08 | 抗ｐｄ１若しくは抗ｐｄｌ１モノクローナル抗体と組み合わせてシチジン類似体の経口製剤を使用する疾患または障害の治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160067336A1 (enExample) |
| EP (1) | EP3191104A1 (enExample) |
| JP (1) | JP2017526700A (enExample) |
| KR (1) | KR20170045237A (enExample) |
| CN (1) | CN106604745A (enExample) |
| AU (1) | AU2015315435A1 (enExample) |
| CA (1) | CA2960490A1 (enExample) |
| EA (1) | EA201790543A1 (enExample) |
| IL (1) | IL250887A0 (enExample) |
| MX (1) | MX2017002875A (enExample) |
| SG (1) | SG11201701710SA (enExample) |
| WO (1) | WO2016040238A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| EP4180041A1 (en) | 2014-08-07 | 2023-05-17 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| US11078278B2 (en) * | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| US11287428B2 (en) | 2016-03-16 | 2022-03-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia |
| KR20190017950A (ko) * | 2016-06-10 | 2019-02-20 | 아이오 테라퓨틱스, 인크. | 암 면역요법을 위한 수용체 선택적 레티노이드 및 렉시노이드 화합물 및 면역 조절제 |
| EP3481422A1 (en) * | 2016-07-06 | 2019-05-15 | Pierre Fabre Medicament | Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination |
| WO2018065938A1 (en) * | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| EP3535295A1 (en) | 2016-11-02 | 2019-09-11 | EngMab Sàrl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| EP3589659B1 (en) | 2017-02-28 | 2025-04-09 | Mayo Foundation for Medical Education and Research | Combinations for use in the treatment of cancer |
| RU2019138507A (ru) * | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| EP3624848A1 (en) | 2017-05-19 | 2020-03-25 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| WO2019014492A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RETINOID COMPOUNDS AND IMMUNOMODULATORY REXINOIDS IN COMBINATION WITH IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER |
| JP2020532537A (ja) | 2017-08-31 | 2020-11-12 | アイオー セラピューティクス インコーポレイテッド | がん免疫治療法のための免疫調節物質と併せたｒａｒ選択的アゴニスト |
| EP3880191A4 (en) * | 2018-11-13 | 2022-08-10 | Yee, Amy | COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY |
| US20220143179A1 (en) * | 2019-03-04 | 2022-05-12 | North Carolina State University | Drug delivery for combination of epigenetic modulation and immune checkpoint blockade |
| WO2020257671A1 (en) | 2019-06-20 | 2020-12-24 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| KR20210097882A (ko) * | 2020-01-30 | 2021-08-10 | 삼성바이오에피스 주식회사 | 안정한 항-pd-1 항체 약제학적 제제 |
| BR112022020285A2 (pt) * | 2020-04-07 | 2022-12-06 | Metanoi Therapeutics Inc | Formulação de etanolamina para tratar carcinoma epitelial de ovário |
| CN118354759A (zh) | 2021-10-19 | 2024-07-16 | 阿基拉比奥有限公司 | 包含2’-脱氧胞苷类似物的组合物及其用于治疗镰状细胞病、地中海贫血和癌症的用途 |
| WO2025042742A1 (en) | 2023-08-18 | 2025-02-27 | Bristol-Myers Squibb Company | Compositions comprising antibodies that bind bcma and cd3 and methods of treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) * | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| PL2342226T3 (pl) * | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| JP6063628B2 (ja) * | 2009-02-10 | 2017-01-18 | セルジーン インターナショナル サルル | ５−アザシチジンを用いる、非小細胞肺癌の治療方法 |
| US20130071403A1 (en) * | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| US20140357567A1 (en) * | 2011-11-01 | 2014-12-04 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
| WO2014128245A1 (en) * | 2013-02-21 | 2014-08-28 | CORAL, Sandra | Dna hypomethylating agents for cancer therapy |
| US10966998B2 (en) * | 2013-09-05 | 2021-04-06 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
-
2015
- 2015-09-08 AU AU2015315435A patent/AU2015315435A1/en not_active Abandoned
- 2015-09-08 WO PCT/US2015/048812 patent/WO2016040238A1/en not_active Ceased
- 2015-09-08 JP JP2017513044A patent/JP2017526700A/ja active Pending
- 2015-09-08 CN CN201580048157.4A patent/CN106604745A/zh not_active Withdrawn
- 2015-09-08 SG SG11201701710SA patent/SG11201701710SA/en unknown
- 2015-09-08 CA CA2960490A patent/CA2960490A1/en not_active Abandoned
- 2015-09-08 EP EP15766985.4A patent/EP3191104A1/en not_active Withdrawn
- 2015-09-08 EA EA201790543A patent/EA201790543A1/ru unknown
- 2015-09-08 KR KR1020177006031A patent/KR20170045237A/ko not_active Abandoned
- 2015-09-08 US US14/847,570 patent/US20160067336A1/en not_active Abandoned
- 2015-09-08 MX MX2017002875A patent/MX2017002875A/es unknown
-
2017
- 2017-03-02 IL IL250887A patent/IL250887A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Feagan et al. | Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin | |
| Huang et al. | Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial | |
| Orman et al. | Clinical and histopathologic features of fluoroquinolone-induced liver injury | |
| JP6787792B2 (ja) | がんの処置のための併用治療 | |
| CN109310763B (zh) | 用于癌症免疫疗法的受体选择性类视黄醇和rexinoid化合物和免疫调节剂 | |
| Hwang et al. | A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer | |
| JP2023516936A5 (enExample) | ||
| Song et al. | Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1 | |
| Landrum et al. | A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: an NRG oncology/gynecologic oncology group study | |
| Qian et al. | Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo | |
| CN108883132A (zh) | 用于治疗癌症的方法 | |
| JP2019517485A5 (enExample) | ||
| JP2019510785A (ja) | 癌を処置する方法 | |
| TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| KR20140040728A (ko) | Pi3k 억제제 화합물을 사용한 중피종 치료 방법 | |
| JP2020523384A5 (enExample) | ||
| WO2016168730A1 (en) | Combination treatments with seribantumab | |
| JP2023510199A5 (enExample) | ||
| Boardman et al. | A phase I evaluation of extended field radiation therapy with concomitant cisplatin chemotherapy followed by paclitaxel and carboplatin chemotherapy in women with cervical carcinoma metastatic to the para-aortic lymph nodes: an NRG oncology/gynecologic oncology group study | |
| Chaudhary et al. | Combinatorial effect of arsenic and herbal compounds in telomerase-mediated apoptosis induction in liver cancer | |
| CA2796624A1 (en) | Method of treating hepatocellular carcinoma | |
| JP2020521786A5 (enExample) | ||
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| Haley et al. | Implementation of BPaL in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant TB disease | |
| Khwaja et al. | High responses rates with single agent belantamab mafodotin in relapsed systemic AL amyloidosis |